Molecule Details
InChIKeyJLYAXFNOILIKPP-KXQOOQHDSA-N
Compound NameAbt 263
Canonical SMILESCC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)7
Pfam Stratification Cross-Family
Avg pChEMBL7.23
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB12340
Drug NameNavitoclax
CAS Number923564-51-6
Groups investigational
ATC Codes L01XX78
DescriptionNavitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others. Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family protei...

Categories: Amides Amines Antineoplastic Agents Antineoplastic and Immunomodulating Agents Sulfones Sulfur Compounds
Cross-references: BindingDB: 50270877 ChEBI: 131174 CHEMBL443684 ChemSpider: 21864722 PDB: 1XJ PubChem:24978538 PubChem:347828599 Wikipedia: Navitoclax ZINC: ZINC000150338726
Target Activities (7)
Target Gene Organism Category Pfam pChEMBL Type Source
O43521 BCL2L11 Homo sapiens Human PF08945 PF06773 8.4 IC50 ChEMBL
P10415 BCL2 Homo sapiens Human PF00452 PF02180 8.0 Kd ChEMBL;BindingDB
Q07817 BCL2L1 Homo sapiens Human PF00452 PF02180 7.4 Ki ChEMBL;BindingDB
Q92934 BAD Homo sapiens Human PF10514 7.3 Kd ChEMBL;BindingDB
Q92843 BCL2L2 Homo sapiens Human PF00452 PF02180 7.2 Ki ChEMBL;BindingDB
Q07820 MCL1 Homo sapiens Human PF00452 6.3 Ki ChEMBL;BindingDB
Q12797 ASPH Homo sapiens Human PF05279 PF05118 PF13432 6.1 IC50 ChEMBL;BindingDB
DrugBank Target Actions (5)
Target Gene Target Name Action Type
Q92934 BAD Bcl2-associated agonist of cell death binder targets
P10415 BCL2 Apoptosis regulator Bcl-2 inhibitor targets
P24385 CCND1 G1/S-specific cyclin-D1 inhibitor targets
Q07817 BCL2L1 Bcl-2-like protein 1 inhibitor targets
Q92843 BCL2L2 Bcl-2-like protein 2 inhibitor targets